Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: Variation by age and sex

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 6, 2004, Pages 828-833

  Qiu, C ^a,b   Kivipelto, M ^b   Aguero Torres H ^b   Winblad, B ^b   Fratiglioni, L ^b  

^a STOCKHOLM GERONTOLOGY RESEARCH CENTER   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SWEDEN; VARIATION (GENETICS);

EID: 2442665411     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.021493     Document Type: Article

References (40)

1. National Institute on Aging/Alzheimer's Association Working Group. Apalipapratein E genatyping in Alzheimer's disease. Lancet 1996;347:1091-5.
2. Kivipelto M, Helkala E-L, Laakso MP, et al. Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55.
3. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64.
4. van Duijn CM, De Knijff P, Wehnert A, et al. The apolipoprotein E ε2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-10.
5. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-56.
6. Katzman R, Zhang M-Y, Chen PJ, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai survey of dementia. Neurology 1997;49:779-85.
7. Ganguli M, Chaandra V, Kamboh MI, et al. Apoplipoprotein E polymophism and Alzheimer disease: the Indo-US cross-national dementia study. Arch Neurol 2000;57:824-30.
8. Frikke-Schmidt R, Nordestgaord BG, Thudium D, et al. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology 2001;56:194-200.
9. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321-2.
10. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotype from a population-based incidence study: the Rotterdam study. Arch Neurol 1998;55:964-8.
11. Yip AG, Brayne C, Easton D, et al. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet 2002;39:639-43.
12. Wilson RS, Bienias JL, Berry-Kravis E, et al. The apolipoprotein E ε2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 2002;73:672-7.
13. Tang M-X, Stern Y, Marder K, et al. The APOE-ε4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-5.
14. Juva K, Verkkoniemi A, Viramo P, et al. APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412-15.
15. Miech RA, Breitner JCS, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002;58:209-18.
16. Kivipelto M, Helkala E-L, Nissinen A, et al. Vascular risk factors, ApoE ε4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Dev Res 2002;56:85-94.
17. Anttila T, Helkala E-L, Kivipelto M, et al. Midlife income, occupation, APOE status, and dementia: a population-based study. Neurology 2002;59:887-93.
18. Molero AE, Pino-Ramírez G, Maestre GE. Modulation by age and gender of risk for Alzheimer disease and vascular dementia associated with the apolipoprotein E-ε4 allele in Latin Americans: findings from the Maracaibo aging study. Neurosci Lett 2001;307:5-8.
19. Fratiglioni L, Viitanen M, Bäckman L, et al. Occurrence of dementia in advanced age: the study design of the Kungsholmen project. Neuroepidemiology 1992;11(suppl 1):29-36.
20. Fratiglioni L, Viitanen M, von Strauss E, et al. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen project, Stockholm. Neurology 1997;48:132-8.
21. Qiu CX, Bäckman L, Winblad B, et al. The influence of education on clinically diagnosed dementia: incidence and mortality data from the Kungsholmen project. Arch Neurol 2001;58:2034-9.
22. Basun H, Corder EH, Guo Z, et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke 1996;27:1310-15.
23. Nordic Council on Medicines. Guidelines for ATC Classification. Uppsala, Sweden: Nordic Council on Medicines, 1985 (NLN Publication no 16).
24. Fratiglioni L, Grut M, Forsell Y, et al. Clinical diagnosis of Alzheimer's disease and other dementias in a population survey: agreement and causes of disagreement in applying Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria. Arch Neurol 1992;49:927-32.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised third edition (DSM-III-R). Washington, DC: American Psychiatric Association, 1987.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
27. Kelsey JL, Thompson WD, Evans AS. Methods in observational epidemiology. New York: Oxford University Press, 1986.
28. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996;40:55-66.
29. Payami H, Zareparsi S, Montee KR, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996;58:803-11.
30. Mortensen EL, Hagh P. A gender difference in the assaciatian between APOE genotype and age-related cognitive decline. Neurology 2001;57:89-95.
31. Kukull WA, Higdan R, Bawen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737-46.
32. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;60:185-9.
33. Polvikoski T, Sulkava R, Hattia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995;333:1242-7.
34. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E-ε2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997;48:515-19.
35. Zhu L, Fratiglioni L, Guo Z, et al. Incidence of dementia in relation to stroke and the apolipoprotein E ε4 allele in the very old: findings from a population-based longitudinal study. Stroke 2000;31:53-60.
36. Guo Z, Fratiglioni L, Viitanen M, et al. Apolipoprotein E genotypes and incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication? Am J Epidemiol 2001;153:225-31.
37. Ghebremedhin E, Schultz C, Thal DR, et al. Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001;56:1696-701.
38. Reilly SL, Ferrell RE, Kottke BA, et al. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota: regression relationships with concomitants. Am J Hum Genet 1992;51:1311-24.
39. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham heart study. Atherosclerosis 2001;154:529-37.
40. Hofman A, Ott A, Breteler MB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997;349:151-4.